The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele
Authors:
- 16 May 2014
- journal article
- research article
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 21 (9) , 1419-1431
Abstract
P53 loss of heterozygosity (p53LOH) is frequently observed in Li-Fraumeni syndrome (LFS) patients who carry a mutant (Mut) p53 germ-line mutation. Here, we focused on elucidating the link between p53LOH and tumor development in stem cells (SCs). Although adult mesenchymal stem cells (MSCs) robustly underwent p53LOH, p53LOH in induced embryonic pluripotent stem cells (iPSCs) was significantly attenuated. Only SCs that underwent p53LOH induced malignant tumors in mice. These results may explain why LFS patients develop normally, yet acquire tumors in adulthood. Surprisingly, an analysis of single-cell sub-clones of iPSCs, MSCs and ex vivo bone marrow (BM) progenitors revealed that p53LOH is a bi-directional process, which may result in either the loss of wild-type (WT) or Mut p53 allele. Interestingly, most BM progenitors underwent Mutp53LOH. Our results suggest that the bi-directional p53LOH process may function as a cell-fate checkpoint. The loss of Mutp53 may be regarded as a DNA repair event leading to genome stability. Indeed, gene expression analysis of the p53LOH process revealed upregulation of a specific chromatin remodeler and a burst of DNA repair genes. However, in the case of loss of WTp53, cells are endowed with uncontrolled growth that promotes cancer.Keywords
This publication has 55 references indexed in Scilit:
- Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytomaNature Genetics, 2013
- The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma developmentOncogene, 2012
- Modeling sarcomagenesis using multipotent mesenchymal stem cellsCell Research, 2011
- A continuum model for tumour suppressionNature, 2011
- Somatic coding mutations in human induced pluripotent stem cellsNature, 2011
- Direct cell reprogramming is a stochastic process amenable to accelerationNature, 2009
- The promises and perils of p53Nature, 2009
- Loss of p53 Induces Tumorigenesis in p21-Deficient Mesenchymal Stem CellsNeoplasia, 2009
- In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like stateNature, 2007
- Li-Fraumeni syndrome – a molecular and clinical reviewBritish Journal of Cancer, 1997